Company intelligence / Profile preview
Alpha Cancer Technologies Inc.
Toronto, Ontario, Canadaalpha-cancer.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
ACT-101 has been shown to be as safe as placebo in clinical trials in over 300 patients. The company is ready to enter Phase II clinical trials in Myasthenia Gravis and Inflammatory Bowel Disease. Their oncology products have demonstrated excellent safety and significant anti-tumor activity in pre-clinical studies.
- Therapeutic areas
- GastroenterologyOncologyNeurologyHematology
- Modalities
- Protein Drug ConjugatesRecombinant human alpha fetoproteinAntibody-drug conjugatesRadiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Bristol-Myers Squibb (14% equity shareholder with no other commercial rights)
Beyond the preview
Go deeper on Alpha Cancer Technologies Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha Cancer Technologies Inc..